**Table S1.** **Comparison of baseline characteristics between the Zhongshan and Ruijin cohorts**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **Zhongshan cohort,**  ***n*=492** | **Ruijin cohort,**  ***n*=167** | ***p*-value** |
| Age in years | 57.0 (50.0-64.0) | 57 (51.5-67.0) | 0.083 |
| Sex |  |  | <0.001 |
| Male | 428 (87.0%) | 117 (70.1%) |  |
| Female | 64 (13.0%) | 50 (29.9%) |  |
| Diabetes |  |  | 0.375 |
| No | 417 (84.8%) | 136 (81.4%) |  |
| Yes | 75 (15.2%) | 31 (18.6%) |  |
| HBsAg |  |  | <0.001 |
| - | 90 (18.3%) | 74 (45.1%) |  |
| + | 402 (81.7%) | 90 (54.9%) |  |
| HBeAg |  |  | 0.978 |
| - | 405 (82.3%) | 135 (82.8%) |  |
| + | 87 (17.7%) | 28 (17.2%) |  |
| Hb in g/L | 142.0 (129.0-152.0) | 138.0 (127.0-151.0) | 0.088 |
| WBC as ×109/L | 5.3 (4.3-6.5) | 4.9 (4.0-5.8) | 0.002 |
| PLT as ×109/L | 152.0 (108.0-201.0) | 145.0 (106.0-188.0) | 0.196 |
| TB in μmol/L | 11.9 (8.8-16.2) | 14.9 (12.05-20.5) | <0.001 |
| ALB in g/L | 42.0 (39.0-45.0) | 39.0 (37.0-42.0) | <0.001 |
| P-ALB in g/L | 0.2 (0.17-0.26) | 0.2 (0.17-0.23) | 0.004 |
| ALT in U/L | 29.0 (20.0-43.0) | 25.0 (18.0-43.0) | 0.033 |
| GGT in U/L | 58.5 (34.0-111.3) | 40.0 (26.5-80.0) | <0.001 |
| INR | 1.01 (0.97-1.06) | 1.01 (0.96-1.06) | 0.479 |
| Gastroesophageal varices |  |  | 0.001 |
| No | 444 (90.2%) | 134 (80.2%) |  |
| Yes | 48 (9.8%) | 33 (19.8%) |  |
| Splenomegaly |  |  | <0.001 |
| No | 122 (24.8%) | 128 (77.1%) |  |
| Yes | 370 (75.2%) | 38 (22.9%) |  |
| Extent of resection |  |  | 0.272 |
| Minor, <3 Couinaud’s segments | 363 (73.8%) | 131 (78.4%) |  |
| Major, ≥3 Couinaud’s segments | 129 (26.2%) | 36 (21.6%) |  |
| Intraoperative blood loss in mL | 200.0 (100.0, 300.0) | 300.0 (100.0, 500.0) | <0.001 |
| Causes of hepatectomy |  |  | <0.001 |
| Malignant tumor | 491 (99.8%) | 135 (80.8%) |  |
| Benign tumor | 1 (0.2%) | 32 (19.2%) |  |
| PALBI | -2.6 (-2.8, -2.4) | -2.5 (-2.7, -2.3) | <0.001 |
| ALBI | -2.9 (-3.2, -2.6) | -2.6 (-2.8, -2.3) | <0.001 |
| MELD | 6.4 (4.0-7.4) | 7.0 (6.4-8.0) | <0.001 |
| *Clinical outcomes* |  |  |  |
| PHLF† |  |  | <0.001 |
| No | 368 (74.8%) | 150 (89.8%) |  |
| Yes | 124 (25.2%) | 17 (10.2%) |  |
| PHLF grade‡ |  |  | <0.001 |
| 0 | 368 (74.8%) | 150 (89.8%) |  |
| A | 87 (17.7%) | 12 (7.2%) |  |
| B | 27 (5.5%) | 3 (1.8%) |  |
| C | 10 (2%) | 2 (1.2%) |  |

†PHLF was defined as postoperative deterioration of liver function with an increase in the INR and concomitant hyperbilirubinemia on or after postoperative day 5 as proposed by the ISGLS. ‡Following the ISGLS definition of PHLF grade.